{"id":44125,"date":"2023-01-01T00:00:00","date_gmt":"2023-01-01T00:00:00","guid":{"rendered":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/"},"modified":"2023-01-01T00:00:00","modified_gmt":"2023-01-01T00:00:00","slug":"a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/","title":{"rendered":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies &#8211; Clin Cancer Res"},"content":{"rendered":"<p>Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P,\u00a0Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, &#8211; 2023<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P,\u00a0Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, &#8211; 2023<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2403],"tags":[],"class_list":["post-44125","post","type-post","status-publish","format-standard","hentry","category-publicaciones-be-21"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima\" \/>\n<meta property=\"og:description\" content=\"Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P,\u00a0Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, &#8211; 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-01T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"A Phase I\\\/II Open-Label Study of Molibresib for the Treatment of Relapsed\\\/Refractory Hematologic Malignancies &#8211; Clin Cancer Res\",\"datePublished\":\"2023-01-01T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/\"},\"wordCount\":67,\"commentCount\":0,\"articleSection\":[\"Publicaciones - BE-21\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/\",\"name\":\"A Phase I\\\/II Open-Label Study of Molibresib for the Treatment of Relapsed\\\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2023-01-01T00:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Phase I\\\/II Open-Label Study of Molibresib for the Treatment of Relapsed\\\/Refractory Hematologic Malignancies &#8211; Clin Cancer Res\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/","og_locale":"es_ES","og_type":"article","og_title":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima","og_description":"Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P,\u00a0Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, &#8211; 2023","og_url":"https:\/\/ibima.eu\/es\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/","og_site_name":"Ibima","article_published_time":"2023-01-01T00:00:00+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies &#8211; Clin Cancer Res","datePublished":"2023-01-01T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/"},"wordCount":67,"commentCount":0,"articleSection":["Publicaciones - BE-21"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/","url":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/","name":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies - Clin Cancer Res - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2023-01-01T00:00:00+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/a-phase-i-ii-open-label-study-of-molibresib-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-clin-cancer-res\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies &#8211; Clin Cancer Res"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/44125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=44125"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/44125\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=44125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=44125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=44125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}